QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.62 (-2.23%)
META   147.81 (-2.59%)
GOOGL   97.14 (-2.24%)
AMZN   100.87 (-1.34%)
TSLA   169.73 (-4.59%)
NVDA   194.08 (-4.70%)
NIO   12.04 (-5.27%)
BABA   111.59 (-5.74%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.16 (-2.68%)
F   12.94 (-2.49%)
CGC   2.88 (-1.71%)
GE   80.93 (-2.76%)
DIS   108.18 (-1.24%)
AMC   4.97 (-9.80%)
PFE   43.47 (-0.73%)
PYPL   80.35 (-1.81%)
NFLX   354.20 (-1.82%)
QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.62 (-2.23%)
META   147.81 (-2.59%)
GOOGL   97.14 (-2.24%)
AMZN   100.87 (-1.34%)
TSLA   169.73 (-4.59%)
NVDA   194.08 (-4.70%)
NIO   12.04 (-5.27%)
BABA   111.59 (-5.74%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.16 (-2.68%)
F   12.94 (-2.49%)
CGC   2.88 (-1.71%)
GE   80.93 (-2.76%)
DIS   108.18 (-1.24%)
AMC   4.97 (-9.80%)
PFE   43.47 (-0.73%)
PYPL   80.35 (-1.81%)
NFLX   354.20 (-1.82%)
QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.62 (-2.23%)
META   147.81 (-2.59%)
GOOGL   97.14 (-2.24%)
AMZN   100.87 (-1.34%)
TSLA   169.73 (-4.59%)
NVDA   194.08 (-4.70%)
NIO   12.04 (-5.27%)
BABA   111.59 (-5.74%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.16 (-2.68%)
F   12.94 (-2.49%)
CGC   2.88 (-1.71%)
GE   80.93 (-2.76%)
DIS   108.18 (-1.24%)
AMC   4.97 (-9.80%)
PFE   43.47 (-0.73%)
PYPL   80.35 (-1.81%)
NFLX   354.20 (-1.82%)
QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.62 (-2.23%)
META   147.81 (-2.59%)
GOOGL   97.14 (-2.24%)
AMZN   100.87 (-1.34%)
TSLA   169.73 (-4.59%)
NVDA   194.08 (-4.70%)
NIO   12.04 (-5.27%)
BABA   111.59 (-5.74%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.16 (-2.68%)
F   12.94 (-2.49%)
CGC   2.88 (-1.71%)
GE   80.93 (-2.76%)
DIS   108.18 (-1.24%)
AMC   4.97 (-9.80%)
PFE   43.47 (-0.73%)
PYPL   80.35 (-1.81%)
NFLX   354.20 (-1.82%)
NASDAQ:URGN

UroGen Pharma - URGN Stock Forecast, Price & News

$10.25
+0.90 (+9.63%)
(As of 01/30/2023 03:12 PM ET)
Add
Compare
Today's Range
$9.42
▼
$10.72
50-Day Range
$7.55
▼
$9.35
52-Week Range
$4.85
▼
$12.63
Volume
141,124 shs
Average Volume
115,264 shs
Market Capitalization
$233.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

UroGen Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
76.1% Upside
$18.00 Price Target
Short Interest
Healthy
2.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
1.43mentions of UroGen Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$3,057 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.50) to ($3.54) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

149th out of 1,049 stocks

Pharmaceutical Preparations Industry

64th out of 514 stocks

See Top Rated MarketRank™ Stocks Here

URGN stock logo

About UroGen Pharma (NASDAQ:URGN) Stock

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. The firm's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Its approved product Jelmyto (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer respectively. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

URGN Stock News Headlines

January 11, 2023 | markets.businessinsider.com
UroGen Reports Results Of First Post-Commercial Utilization Review Of JELMYTO
January 11, 2023 | finance.yahoo.com
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
January 30, 2023 | Investing Trends (Ad)
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
January 9, 2023 | finance.yahoo.com
The past five years for UroGen Pharma (NASDAQ:URGN) investors has not been profitable
December 22, 2022 | seekingalpha.com
URGN UroGen Pharma Ltd.
December 19, 2022 | finance.yahoo.com
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
December 13, 2022 | finance.yahoo.com
With 57% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns
December 2, 2022 | finance.yahoo.com
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
January 30, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 2, 2022 | markets.businessinsider.com
UroGen : Phase 3 Data Show JELMYTO Provides Effective & Durable Kidney-sparing Treatment Option
December 1, 2022 | finance.yahoo.com
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
November 21, 2022 | finance.yahoo.com
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
November 21, 2022 | seekingalpha.com
UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns Remain
November 16, 2022 | finance.yahoo.com
Some Analysts Just Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Estimates
November 14, 2022 | finance.yahoo.com
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
November 12, 2022 | finance.yahoo.com
UroGen Pharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
November 10, 2022 | seekingalpha.com
UroGen Pharma Ltd. (URGN) Q3 2022 Earnings Call Transcript
November 10, 2022 | finance.yahoo.com
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 10, 2022 | finance.yahoo.com
Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates
November 9, 2022 | finance.yahoo.com
UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
November 3, 2022 | finance.yahoo.com
UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
October 11, 2022 | finance.yahoo.com
10 Best Immunotherapy Stocks To Buy Now
October 11, 2022 | finance.yahoo.com
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
October 1, 2022 | finance.yahoo.com
UroGen Pharma Ltd. (URGN)
September 28, 2022 | markets.businessinsider.com
UroGen Pharma Announces Label Change For JELMYTO - Quick Facts
September 28, 2022 | finance.yahoo.com
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution
September 12, 2022 | finance.yahoo.com
UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors
See More Headlines
Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

URGN Company Calendar

Last Earnings
11/10/2022
Today
1/30/2023
Next Earnings (Estimated)
3/20/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:URGN
CUSIP
N/A
CIK
1668243
Web
www.urogen.com
Phone
(646) 768-9780
Fax
N/A
Employees
195
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+75.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-110,820,000.00
Net Margins
-175.16%
Pretax Margin
-171.63%
Return on Equity
N/A
Return on Assets
-78.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.40
Quick Ratio
6.14

Sales & Book Value

Annual Sales
$48.04 million
Price / Sales
4.85
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
22,740,000
Free Float
19,557,000
Market Cap
$233.09 million
Optionable
Optionable
Beta
0.78

Key Executives

  • Elizabeth BarrettElizabeth Barrett
    President, Chief Executive Officer & Director
  • Dong Kim
    Chief Financial & Accounting Officer
  • Marina Konorty
    EVP-Research & Development & Technical Operations
  • Mark P. SchoenbergMark P. Schoenberg
    Chief Medical Officer
  • Moran Mieron
    Director-Research & Pre-Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













URGN Stock - Frequently Asked Questions

Should I buy or sell UroGen Pharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" URGN shares.
View URGN analyst ratings or view top-rated stocks.

What is UroGen Pharma's stock price forecast for 2023?

3 Wall Street analysts have issued 1 year price objectives for UroGen Pharma's shares. Their URGN share price forecasts range from $11.00 to $23.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 92.5% from the stock's current price.
View analysts price targets for URGN or view top-rated stocks among Wall Street analysts.

How have URGN shares performed in 2023?

UroGen Pharma's stock was trading at $8.87 at the start of the year. Since then, URGN stock has increased by 5.4% and is now trading at $9.35.
View the best growth stocks for 2023 here.

Are investors shorting UroGen Pharma?

UroGen Pharma saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 569,600 shares, a decrease of 15.2% from the December 31st total of 671,700 shares. Based on an average daily volume of 73,500 shares, the days-to-cover ratio is currently 7.7 days. Approximately 2.9% of the shares of the company are short sold.
View UroGen Pharma's Short Interest.

When is UroGen Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 20th 2023.
View our URGN earnings forecast.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) issued its quarterly earnings results on Thursday, November, 10th. The company reported ($1.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.09. The firm had revenue of $16.10 million for the quarter, compared to the consensus estimate of $20.30 million.

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Who are UroGen Pharma's major shareholders?

UroGen Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (0.87%) and Rice Hall James & Associates LLC (0.32%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg, Molly Henderson, Peter P Pfreundschuh and Stephen Mullennix.
View institutional ownership trends.

How do I buy shares of UroGen Pharma?

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $9.35.

How much money does UroGen Pharma make?

UroGen Pharma (NASDAQ:URGN) has a market capitalization of $212.62 million and generates $48.04 million in revenue each year. The company earns $-110,820,000.00 in net income (profit) each year or ($4.83) on an earnings per share basis.

How many employees does UroGen Pharma have?

The company employs 195 workers across the globe.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for the company is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com.

This page (NASDAQ:URGN) was last updated on 1/30/2023 by MarketBeat.com Staff